Generic drugmaker Mylan has proposed buying Perrigo for about $ 29 billion in cash and stock in what would be the biggest pharmaceutical deal of the year so far.
Not exact matches
Teva Pharmaceuticals has proposed buying rival
Mylan for $ 40 billion in cash and stock, as the Israel - based
drugmaker looks to gain dominance among
generic pharmaceutical companies.
The four companies that challenged the Restasis patents include Teva Pharmaceuticals, the world's largest
generic drugmaker, as well as
Mylan Pharmaceuticals, Apotex, and Akorn.
Mylan NV Executive Chairman Robert Coury was named chairman of the
generic drugmaker's board in a move that reduces his role in management of the company and could give Heather Bresch greater responsibilities as chief executive.